title: [Magnesium sulfate in the prophylaxis of eclampsia: a retrospective study].
abstract: BACKGROUND
  The use of magnesium sulfate (MgSO(4)) has been advocated since 2000 in France in the management of eclampsia. The aim of this study was to determine the frequency of use of this treatment for eclampsia in a French department.
  
  
  METHODS
  All patients obstetrical patients admitted to Critical Care Units of Seine-Maritime for eclampsia over a period of 7 years (2002-2008) were included. Obstetric data, the treatment used for eclampsia and pre-eclampsia and maternofetal complications were collected. The primary outcome parameter was the use of MgSO(4) in the secondary prevention of eclampsia.
  
  
  RESULTS
  Thirty-nine patients were included. Nineteen patients (48%) had eclampsia in prepartum, three (8%) in per-partum and 17 (44%) in post-partum periods. The use of MgSO(4) in the secondary prevention of eclampsia was observed in 92% of cases (36/39). Primary prevention was seen in 8% of cases. The duration of treatment was 2 days (1-7 days). The maternal and perinatal mortality was respectively 2.5 and 11%.
  
  
  CONCLUSIONS
  In this study, the use of MgSO(4) in the secondary prevention is frequent. This result emphasizes the importance of the recommendations of learned societies in the homogenization of the management of rare but serious conditions such as eclampsia.
authors.affiliation: Département d'anesthésie-réanimation chirurgicale et samu, centre hospitalier universitaire de Rouen, 1 rue de Germont, Rouen, France.
authors.forename: B
authors.initials: B
authors.lastname: Bourret
authors.forename: V
authors.initials: V
authors.lastname: Compère
authors.forename: S
authors.initials: S
authors.lastname: Torre
authors.forename: K
authors.initials: K
authors.lastname: Azhougagh
authors.forename: D
authors.initials: D
authors.lastname: Provost
authors.forename: B
authors.initials: B
authors.lastname: Rachet
authors.forename: R
authors.initials: R
authors.lastname: Gillet
authors.forename: M
authors.initials: M
authors.lastname: Rieu
authors.forename: L
authors.initials: L
authors.lastname: Marpeau
authors.forename: B
authors.initials: B
authors.lastname: Dureuil
mesh_terms: D000293:Adolescent; D000328:Adult; D001034:Apgar Score; D003422:Critical Care; D004461:Eclampsia / Q000401:mortality / Q000517:prevention & control*; D005260:Female; D005313:Fetal Death; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy; D007231:Infant, Newborn; D008278:Magnesium Sulfate / Q000009:adverse effects / Q000627:therapeutic use*; D054238:Perinatal Mortality; D011225:Pre-Eclampsia / Q000517:prevention & control; D011247:Pregnancy; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D015149:Tocolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D015149:Tocolytic Agents; D008278:Magnesium Sulfate